ReShape Lifesciences

ReShape Lifesciences, Inc. is a medical device company, which focuses on technology to treat obesity and metabolic diseases. Its portfolio includes the Lap-Band Adjustable Gastric Banding System, ReShape Marketplace, Obalon Balloon System, ReShape Vest, and Diabetes Bloc-Stim Neuromodulation device. The company was founded in December 2002 and is headquartered in San Clemente, CA.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ReShape Lifesciences, Inc. is a medical device company, which focuses on technology to treat obesity and metabolic diseases. Its portfolio includes the Lap-Band Adjustable Gastric Banding System, ReShape Marketplace, Obalon Balloon System, ReShape Vest, and Diabetes Bloc-Stim Neuromodulation device. It operates through the United States, Australia, Europe, and Rest of World geographical segments. The company was founded in December 2002 and is headquartered in San Clemente, CA.

The stock price of ReShape Lifesciences Inc (NASDAQ: RSLS) increased by over 20% pre-market. This is why it happened.

RSLS Stock Price Increases Over 20% Pre-Market: Why It Happened

Checkpoint Therapeutics

Equillium Inc

Flexion Therapeutics

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

4 Biotech and Life Sciences Stocks Trading Under $10 With Gigantic Upside Potential

Shares of ReShape Lifesciences commenced trading on The Nasdaq Capital Market at market open on June 16, 2021 under the ticker symbol "RSLS" SAN CLEMENTE, CA / ACCESSWIRE / June 17, 2021 / ReShape Lifesciences Inc. (NASDAQ:RSLS), a global weight-loss solutions leader, announced that its common stock effectively traded at a first day volume of over 3.5 million shares on The Nasdaq Capital Market under the ticker symbol "RSLS", following the previously announced completion of its merger with Obalon Therapeutics, Inc. "Listing on Nasdaq has been one of the Company's top strategic goals, and we are very pleased to have achieved this important milestone," commented Bart Bandy, President and Chief Executive Officer of ReShape Lifesciences. "We are excited to capitalize on the benefits of being a Nasdaq listed company and deliver on our mission to become the premier physician led weight loss solutions company, currently anchored by the Lap-Band® System with over 1,000,000 worldwide placements and the company's recently launched reshapecare™ virtual health program that is reimbursed through many major insurance carriers.

ReShape Lifesciences Closes First Day of Trading on the NASDAQ Capital Market

Shares of ReShape Lifesciences to commence trading on The Nasdaq Capital Market on June 16, 2021 under ticker symbol "RSLS" Combination creates opportunity for ReShape to expand portfolio of FDA approved weight loss solutions and reimbursed virtual care services SAN CLEMENTE, CA / ACCESSWIRE / June 16, 2021 / ReShape Lifesciences Inc. (NASDAQ:RSLS), a global weight-loss solutions leader, today announced the completion of the previously announced merger with Obalon Therapeutics. In connection with the merger's closing, Obalon changed its name to ReShape Lifesciences Inc. and the combined company's common stock will begin trading under the ticker symbol "RSLS" on The Nasdaq Capital Market beginning on June 16, 2021.

ReShape Lifesciences Completes Merger with Obalon Therapeutics

Obalon Therapeutics

SAN CLEMENTE, CA and SAN DIEGO, CA / ACCESSWIRE / June 15, 2021 / ReShape Lifesciences Inc. (OTCQB:RSLS) and Obalon Therapeutics, Inc. (NASDAQ:OBLN) announced today the anticipated closing of their previously announced merger to be effective after the close of the market today, June 15, 2021. The shares of common stock of the combined company are expected to commence trading on The Nasdaq Capital Market on Wednesday, June 16, 2021, under the name ReShape Lifesciences Inc. and the trading symbol "RSLS.

ReShape Lifesciences Inc. and Obalon Therapeutics, Inc. Announce Anticipated Closing of Merger

SAN CLEMENTE, CA and SAN DIEGO, CA / ACCESSWIRE / June 8, 2021 / ReShape Lifesciences Inc. (OTCQB:RSLS) and Obalon Therapeutics, Inc. (NASDAQ:OBLN) announced today that the parties anticipate the closing of their previously announced merger to occur promptly after approval of their pending Nasdaq listing application. While there can be no assurance that the listing application will be approved, Nasdaq approval is the sole remaining condition to closing in the merger agreement (other than conditions that the parties anticipate being satisfied at the closing).

ReShape Lifesciences Inc. and Obalon Therapeutics, Inc. Update on Status of Pending Merger

SAN CLEMENTE, CA / ACCESSWIRE / May 17, 2021 / ReShape Lifesciences Inc. (OTCQB:RSLS), a leading developer and distributor of minimally invasive medical devices to treat obesity and metabolic diseases, today reported its financial and operational results for the three months ended March 31, 2021. Recent Highlights and Accomplishments Increased revenues by 15.5% compared to same period in 2020 Increased revenues by 4.6% compared to non COVID-19 pandemic affected same period in 2019 Continued to implement previously mentioned cost savings plan reducing operating expenses by $1.1 million Improved Non-GAAP loss by $1.6 million Obtained $15.0 million line of credit with instutional investor Received full forgiveness of $1.0 million on PPP loan "2021 has proven to be a transformational year for Reshape, as we continue on our pathway to becoming the premier physician led weight loss company," said Bart Bandy, President, and Chief Executive Officer at ReShape Lifesciences.

ReShape Lifesciences Announces First Quarter 2021 Financial and Operational Results

SAN CLEMENTE, CA / ACCESSWIRE / March 10, 2021 / ReShape Lifesciences Inc. (OTCQB:RSLS), a global weight-loss solutions leader, today reported financial and operational results for the fourth quarter and full year ended December 31, 2020. Recent Highlights and Accomplishments Entered into a definitive merger agreement with Obalon Therapeutics, Inc., a company focused on developing and commercializing novel technologies for weight loss.

ReShape Lifesciences Announces Fourth Quarter and Full Year 2020 Financial Results

Webinar to discuss results on March 10, 2021 at 4:30 p.m. E.T SAN CLEMENTE, CA / ACCESSWIRE / March 8, 2021 / ReShape Lifesciences Inc. (OTCQB:RSLS), a leading developer and distributor of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that it will report its fourth quarter and full year 2020 financial and operational results on Wednesday, March 10, 2021 after the close of the U.S. financial markets.

Reshape Lifesciences to Report Fourth Quarter and Full Year 2020 Financial and Operational Results on Wednesday, March 10, 2021

ReShape Lifesciences' (RSLS) CEO Bart Bandy on Q3 2019 Results - Earnings Call Transcript

ReShape Lifesciences Inc. (RSLS) CEO Bart Bandy on Q2 2019 Results - Earnings Call Transcript

ReShape Lifesciences Inc. (RSLS) CEO Bart Bandy on Q1 2019 Results - Earnings Call Transcript

ReShape Lifesciences Inc.'s (RSLS) CEO Dan Gladney on Q4 2018 Results - Earnings Call Transcript

News for ReShape Lifesciences Stock (RSLS)